Artificial intelligence news.
Straight from the original announcements.

Isomorphic Labs raises $5 billion to scale AI drug discovery

November 17, 2026, 13:17By the AI News Bites Editorial TeamSource: PR Newswire
Top storyIsomorphic Labs raises $5 billion to scale AI drug discovery
Image: PR Newswire

Isomorphic Labs has raised $5 billion in an oversubscribed Series C round to expand its AI drug design engine, develop therapeutic candidates and build infrastructure for AI-led bioengineering. Greenoaks and Sequoia Capital co-led the financing, with continued investment from Alphabet.

Key points
  • $5 billion Series C was co-led by Greenoaks and Sequoia Capital.
  • Alphabet and all existing investors also participated.
  • IsoDDE works across multiple therapeutic areas and drug modalities.
  • Internal oncology and immunology programs have reported positive preclinical results.
  • Funding will support infrastructure and programs moving toward clinical trials.

Funding will expand Isomorphic’s AI drug platform

The London-based company said the round also included Andreessen Horowitz, several other new investors and all of its existing investors: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.

Isomorphic Labs plans to use the capital to scale its proprietary drug design engine, IsoDDE, and its pipeline of therapeutic candidates. The company describes IsoDDE as a suite of foundational simulation AI models that works across multiple therapeutic areas and drug modalities.

According to Isomorphic Labs, IsoDDE explores large chemical spaces and helps its teams design and refine molecules with drug-like properties. The company said the models are intended to push predictions toward experimental accuracy and support the development of medicines across its multi-modality pipeline.

Internal and partnered programs are moving toward clinical entry

Isomorphic Labs said its progress is producing positive preclinical results in internal oncology and immunology programs, as well as in programs developed with partners. The company said these results are setting the stage for clinical entry, although the announcement did not provide a timetable for trials.

The new funding will support further development of IsoDDE and more advanced models focused on biology. Isomorphic also plans to build a partner ecosystem aimed at improving understanding of mechanistic disease biology.

Proceeds will also fund scalable AI-first translational and clinical development infrastructure as the company advances drug candidates toward clinical trials. Isomorphic said it is building global infrastructure to support the future of AI-led bioengineering.

Company says AI advances are translating into candidate medicines

“When we founded Isomorphic, our conviction was that biology could be understood and modelled at the most fundamental molecular level and radically accelerated through AI,” said Sir Demis Hassabis, the company’s founder and CEO. He said the financing would support foundational biology models, deeper systemic disease understanding and the company’s first therapeutic programs as they move toward clinical trials.

President Max Jaderberg said the company was making “repeatable scientific advancements enabled by our models” and translating them into molecular profiles with the potential to become medicines. Isomorphic Labs said its teams combine machine learning researchers with drug discovery specialists.

Founded in 2021, Isomorphic Labs is headquartered in London and has offices in Cambridge, Massachusetts, and Lausanne, Switzerland. The company’s stated focus is to use artificial intelligence to design and develop new medicines. The financing gives it resources to extend its models, expand its candidate pipeline and prepare the infrastructure needed to take those candidates toward clinical development.

Related news

Business
BusinessNovember 19, 2026, 20:27

Isomorphic Labs and MSD Partner on AI-Driven Cancer Drug Discovery

Isomorphic Labs and MSD have agreed to collaborate on discovering small-molecule drug candidates for a strategically important cancer indication. The partnership…

Isomorphic Labs announces $5 billion Series C funding roundTop story
BusinessNovember 18, 2026, 13:39

Isomorphic Labs announces $5 billion Series C funding round

Isomorphic Labs has announced a $5 billion Series C funding round, according to a PR Newswire release dated November 18, 2026. The announcement provides the size and…

Isomorphic Labs announces $5 billion Series C funding roundTop story
BusinessNovember 18, 2026, 13:39

Isomorphic Labs announces $5 billion Series C funding round

Isomorphic Labs has announced a $5 billion Series C financing round, according to a PR Newswire release dated November 18, 2026. The announcement identifies the size and…